Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Fig. 1

LS mean change from baseline in (a) PASDAS, (b) DAPSA, and (c) CPDAI. For complete data, see Additional file 1: Table S1. *P ≤0.05, **P <0.01, ***P <0.001 versus placebo. Abbreviations: BID twice daily, CPDAI Composite Psoriatic Disease Activity Index, DAPSA Disease Activity Index for Psoriatic Arthritis, LS least squares, OPAL Oral Psoriatic Arthritis triaL, PASDAS Psoriatic Arthritis Disease Activity Score, Q2W once every 2 weeks, SC subcutaneous, SE standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us